If you want to know who really controls Alcon Inc. ( VTX:ALC ), then you'll have to look at the makeup of its share registry.

Alcon projects an estimated earnings growth rate of 13.5% for 2025 compared with the S&P 500’s 8%. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alcon (ALC – Research Report) and Iradimed ...

Alcon Inc. (NYSE: ALC) has a price-to-earnings ratio that is above its average at 40.12x. The stock has a 36-month beta value of 0.91. Opinions on the stock are mixed, with 0 analysts rating it as a ...

Browse analyst ratings and price targets on all stocks.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Alcon Inc (Symbol: ALC) entered into oversold territory, hitting an RSI reading of 28.8 ...

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and ...

Alcon is based in Switzerland and engages in the sector 'Manufacturing'. Find out more about Alcon in our report focusing on the company's key figures and information. With this report ...

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Alcon ALC is likely to grow in the coming quarters, backed by the flourishing Surgical business with its diversified portfolio and innovative technologies. Strength in the Vision Care business ...